Literature DB >> 7562934

Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.

E M van der Wenden1, J K von Frijtag Drabbe Künzel, R A Mathôt, M Danhof, A P IJzerman, W Soudijn.   

Abstract

We have adopted a practical three-step route for the synthesis of 2'- and 3'-deoxy analogues of N6-substituted adenosines: protection of the hydroxyl groups, replacement of the N6-amino by a better leaving group, and combined deprotection and N6-amination in the last step. This route was used to synthesize deoxy analogues of CPA, CHA, and R- and S-PIA. The compounds were tested on the adenosine A1 and A2a receptors in our search for partial agonists for these receptors. The GTP shift was used as an in vitro measure for the intrinsic activity of these compounds; the in vivo intrinsic activities of the deoxy analogues of CPA and R-PIA were determined in the rat cardiovascular system. Thus, it was shown that the hydroxyl groups are determinants for the affinity and intrinsic activity of these analogues. Removal of the 2'- and 3'-hydroxyl groups affects affinity and intrinsic activity, whereas removal of the 5'-hydroxyl group decreases only affinity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562934     DOI: 10.1021/jm00020a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Thermodynamic in vitro studies as a method to investigate the pharmacodynamic behavior of adenosine A1 receptor ligands.

Authors:  A Dalpiaz; A Scatturin; B Pavan; K Varani; A P IJzerman; P Andrea Borea
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Two-step, one-pot synthesis of inosine, guanosine, and 2'-deoxyguanosine O6-ethers via intermediate O6-(benzotriazol-1-yl) derivatives.

Authors:  Hari Prasad Kokatla; Mahesh K Lakshman
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2012-06

3.  Optimization of Thermolytic Response to A1 Adenosine Receptor Agonists in Rats.

Authors:  Isaac R Bailey; Bernard Laughlin; Lucille A Moore; Lori K Bogren; Zeinab Barati; Kelly L Drew
Journal:  J Pharmacol Exp Ther       Date:  2017-06-26       Impact factor: 4.030

4.  9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities.

Authors:  Karl-Norbert Klotz; Sonja Kachler; Catia Lambertucci; Sauro Vittori; Rosaria Volpini; Gloria Cristalli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-07       Impact factor: 3.000

5.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.

Authors:  Yolande Cordeaux; Adriaan P Ijzerman; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

6.  Synthesis and characterization of oligodeoxyribonucleotides containing a site-specifically incorporated N6-carboxymethyl-2'-deoxyadenosine or N4-carboxymethyl-2'-deoxycytidine.

Authors:  Jianshuang Wang; Yinsheng Wang
Journal:  Nucleic Acids Res       Date:  2010-05-27       Impact factor: 16.971

7.  Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.

Authors:  Masahiro Ikejiri; Masayuki Saijo; Shigeru Morikawa; Shuetsu Fukushi; Tetsuya Mizutani; Ichiro Kurane; Tokumi Maruyama
Journal:  Bioorg Med Chem Lett       Date:  2007-02-13       Impact factor: 2.823

Review 8.  Partial agonists for A(3) adenosine receptors.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

9.  Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.

Authors:  Zhan-Guo Gao; Soo-Kyung Kim; Thibaud Biadatti; Wangzhong Chen; Kyeong Lee; Dov Barak; Seong Gon Kim; Carl R Johnson; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-09-26       Impact factor: 8.039

10.  Structural and energetic effects of A2A adenosine receptor mutations on agonist and antagonist binding.

Authors:  Henrik Keränen; Hugo Gutiérrez-de-Terán; Johan Åqvist
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.